UBS revises Coloplast rating to neutral, sees lower risk By Investing.com
UBS revises Coloplast rating to neutral, sees lower risk…
802,64DKK
1,55%
Echtzeit-Aktienkurs Coloplast AS
Bid:
Ask:
Nachrichten zur Coloplast AS Aktie
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf.…
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf.…
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf.…
The Convex Ostomy Care Bags Industry: Navigating Towards $4.48 Billion by 2030 with Innovative Comfort Solutions, Dominated by ConvaTec, Coloplast, Hollister Incorporated, and B. Braun
Dublin, May 23, 2024 (GLOBE NEWSWIRE) -- The "Convex Ostomy Care Bags Unveiled: Navigating Towards a US$ 4.48…
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf.…
Urology Devices Market revenue to surpass USD 63 Billion by 2033, says Research Nester
Major urology devices market players include Boston Scientific Corporation, Coloplast A/S, Ethicon, Inc, Ambu A/S, KARL STORZ SE & Co.…
Coloplast: Starke Unternehmenszahlen - Aktie steigt kräftig - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Coloplast-Aktienanalyse von "Der Aktionär":
Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…
Coloplast: Medizingeräte-Hersteller überzeugt – neue Innovation beflügelt
Nach einem Mehrjahrestief Mitte November geht es für den dänischen Medizingerätehersteller Coloplast stetig nach oben. Dabei verleihen die Konzernzahlen und…
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities…
Coloplast Finance B.V. - Decisions at the Annual General Meeting
On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole…
Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET
Friday, 9 February 2024 at 11.00 - 12.00 CETIn connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released…
Coloplast A/S - Decisions at the Annual General Meeting 2023
Today, 7 December 2023, Cololast A/S held its Annual General Meeting, at which the following resolutions were adopted:…
Ostomy Care and Accessories Market Size, Share & Trends Analysis Report 2023-2030, Featuring Profiles of Coloplast, Hollister, B. Braun, Convatec, Welland Medical and Salts Healthcare
Dublin, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The "Ostomy Care And Accessories Market Size, Share & Trends Analysis…
Coloplast announces new manufacturing site in Portugal
Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to…
Coloplast A/S - FY 2023/24 Financial Guidance
Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin…
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf....…
Coloplast ASB reports Q3 results
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Coloplast Finance B.V. - Announcement no. 04/2023 - Interim Financial Report 9M 2022/23
9M 2022/23Interim financial results, 9M 2022/231 October 2022 - 30 June 2023...…
Coloplast A/S - Announcement no. 04/2023 - Interim Financial Report, 9M 2022/2023
9M 2022/23Interim financial results, 9M 2022/231 October 2022 - 30 June 2023...…
Kvika banki hf.: Due to news of a takeover offer in Kerecis hf.
In light of recent announcements about Coloplast A/Ss takeover bid for all share capital in Kerecis (“Kerecis”) hf. Kvika banki…
Coloplast to acquire wound care firm Kerecis for $1.3B
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
VÍS: Áhrif af sölu eignarhluta í Kerecis
VÍS hefur samþykkt sölu á öllum eignarhlut sínum í Kerecis, sem nemur 136.715 hlutum, í tengslum við yfirtökutilboð Coloplast í…
Coloplast buys fish skin woundcare firm for up to $1.3 billion
...COPENHAGEN (Reuters) -Coloplast has agreed to buy Iceland-based......…
UPDATE 2-Coloplast buys fish skin woundcare firm for up to $1.3 bln
...,
background on Kerecis in 7)
COPENHAGEN, July 7 (Reuters) - Coloplast has......…
Coloplast Agrees to Buy Biotechnology Firm Kerecis for Up to $1.3 Billion
Coloplast Agrees to Buy Biotechnology Firm Kerecis for Up to $1.3 Billion...…
Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up…
Largest shareholder and Foundation to secure Coloplast future with new holding company
As part of a generational change, the largest shareholder in Coloplast A/S, Niels Peter Louis-Hansen, will establish a new holding…
XETR : DIVIDEND/INTEREST INFORMATION - 15.05.2023 - DK0060448595
Das Instrument CBHD DK0060448595 COLOPLAST NAM. B DK 1 EQUITY wird ex Dividende/Zinsen gehandelt am 15.05.2023
The instrument…
Coloplast ASB Non-GAAP EPS of DKK5.51, revenue of DKK6.06B
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Coloplast B.V. - Announcement no. 03/2023 - Interim Financial Report H1 2022/23
H1 2022/23...…
Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23
H1 2022/23...…
Global Stoma/Ostomy Care Market Report 2022 to 2027: Featuring 3M, Coloplast, ConvaTec and Flexicare Medical Among Others
DUBLIN, Feb. 16, 2023 /PRNewswire/ -- The "Stoma/Ostomy Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027"…
Coloplast launches male catheter designed to reduce the risk of urinary tract infections
The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent…
Coloplast A/S - Announcement no. 01/2023 – Interim Financial Report, Q1 2022/23
Q1 2022/23...…
Coloplast Finance B.V. - Decisions at the Annual General Meeting
Decisions at the Annual General Meeting...…